Mylacand 8 mg, 16 mg Tablet
PDF Leaflet Revision Date: 19 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate hypertension and heart failure.
Dosage (summary)
Initial dose: 8 mg once daily; maintenance: 8-16 mg once daily; max: 32 mg. Heart failure: Initial 4 mg, titrate to 32 mg.
Onset of Action / Duration
Onset: 4 weeks, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not established in breastfeeding.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity
- Severe renal impairment
- Bilateral renal artery stenosis
- Severe hepatic impairment
- Pregnancy
Common side effects
- Hyperkalaemia
- Hypotension
- Renal impairment
- Dizziness
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Discontinue if pregnancy occurs
Serious warnings
- Risk of hypotension in heart failure patients
- Dual blockade of RAAS contraindicated
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
